Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL502785 | 0.86 | CYP4F2 (0.63) | L3MBTL1KDM4EGLACYP4F2CYP4A11 | |
| SCHEMBL4812296 | 0.84 | KMT2A (0.48) | L3MBTL1KDM4EGLAHPGDALDH1A1 | |
| SCHEMBL5802908 | 0.83 | CA2 (0.50) | KDM4ECYP4F2CYP4A11ALDH1A1HTT | |
| SCHEMBL6795893 | 0.83 | TDP1 (0.50) | L3MBTL1CYP4F2CYP4A11HPGDALDH1A1 | |
| SCHEMBL10140460 | 0.83 | CYP4F2 (0.50) | L3MBTL1KDM4ECYP4F2CYP4A11HPGD | |
| SCHEMBL31048202 | 0.83 | L3MBTL1 (0.44) | L3MBTL1KDM4EGLAHPGDALDH1A1 | |
| SCHEMBL6025472 | 0.81 | ALDH1A1 (0.56) | L3MBTL1CYP4F2CYP4A11ALDH1A1KMT2A | |
| SCHEMBL754043 | 0.81 | KMT2A (0.51) | L3MBTL1KDM4ECYP4F2CYP4A11KMT2A | |
| SCHEMBL5431221 | 0.81 | HTT (0.62) | L3MBTL1KDM4EALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL27348043 | 0.81 | LOXL2 (0.55) | KDM4ECYP4F2CYP4A11ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2805939-B1 | Heterocyclic compounds as factor IXA inhibitors. | MERCK SHARP & DOHME (US) | 2018-06-27 | — | — | EP | disclosed |
| WO-2015140133-A1 | PIPERIDINE-DIONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015142903-A2 | METHOD OF CONTROLLING LACTATE PRODUCTION WITH PIPERDINE-DIONE DERIVATIVES | GENENTECH, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| EP-2805939-A1 | Heterocyclic compounds as factor IXA inhibitors. | Merck Sharp & Dohme Corp. (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8148363-B2 | Heterocyclic compounds as factor IXA inhibitors | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
| WO-2009143039-A2 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | SCHERING CORPORATION (US) | 2009-11-26 | — | — | WO | disclosed |
| US-5712296-A | Substituted pyridines and 2-oxo-1,2-dihydropyridines | BAYER AKTIENGESELLSCHAFT (DE) | 1998-01-27 | — | — | US | disclosed |
| US-5492923-A | DRUG FOR TREATING ARTERIAL HYPERTENSION AND ATHEROSCLEROSIS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-02-20 | — | — | US | disclosed |
| EP-0623610-A1 | Substituted pyridines and 2-oxo-1,2-dihydropyridines as Angiotensine II antagonists | BAYER AG (DE) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | F9, F12, F8 | L3MBTL1 4551/4885KDM4E 1387/4885GLA 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.